Challenges
Arboviral infections represent a growing global public health and clinical burden, especially in tropical and subtropical regions, with rising cross-border transmission risks amid growing international travel and trade. For tertiary hospital infectious disease departments, port quarantine authorities and frontline public health agencies, conventional diagnostic approaches for arboviral pathogens have four core unmet needs:
Highly overlapping symptoms with poor differential diagnostic yield
Most arboviral infections — including dengue, Zika, chikungunya and West Nile fever — present with nearly identical early clinical features such as acute fever, rash, myalgia and arthralgia, with frequent mixed infections in co-endemic areas. Conventional single-target assays and rapid antigen tests have limited coverage and low sensitivity, leading to high missed diagnosis rates. This makes it difficult to clarify etiology for targeted clinical management and early warning of severe cases such as severe dengue.
Delayed centralized testing slows clinical intervention and outbreak response
Traditional nucleic acid testing relies on centralized molecular laboratories, with lengthy sample transport and batch processing workflows that take hours to days to deliver results. For time-sensitive conditions like dengue, delayed diagnosis directly worsens patient prognosis. For port quarantine and outbreak scenarios, slow testing also hinders timely infection control implementation and source tracing.
High operational barriers limit deployment in endemic and frontline settings
Conventional molecular diagnostics require standardized PCR laboratories and certified technical personnel. These conditions are often unavailable in high-prevalence tropical regions, grassroots medical facilities, border ports and field outbreak sites, resulting in extremely limited access to reliable arboviral testing.
Mounting pressure for imported arboviral disease prevention and control
Growing cross-border travel and trade have steadily increased the risk of imported cases of dengue, yellow fever, Zika and other arboviral infections. Frontline quarantine sites lack fast on-site screening tools, creating risks of local community transmission following importation.
Core Benefits
The 8 Arboviral Pathogen Nucleic Acid Detection Kit, paired with the Multi-Disc fully automated nucleic acid analysis platform, directly addresses the above clinical and public health pain points:
One-stop 8-plex pathogen profiling for accurate differential diagnosis
A single run covers 8 globally prevalent pathogenic arboviruses, including 4 dengue virus serotypes (DENV-1/2/3/4), Zika virus, chikungunya virus, yellow fever virus and West Nile virus. It accurately identifies single and mixed infections with clear serotype differentiation, eliminating the need for sequential separate testing and greatly improving diagnostic efficiency for acute febrile illness workup.
Results in around 80 minutes to capture critical diagnosis and response windows
Total testing time is around 80 minutes, with only 1 minute of hands-on sample loading — far faster than centralized laboratory workflows. Rapid etiological results support early warning of severe dengue and timely clinical management, while also enabling on-site rapid quarantine at ports of entry to block imported case spread.
Low-barrier POCT deployment to expand decentralized testing access
Powered by the fully automated closed Multi-Disc platform, the assay requires no standardized molecular laboratory or specialized technical staff, and can be deployed directly in infectious disease outpatient departments, grassroots clinics, border quarantine stations and field outbreak sites. Samples can be tested immediately upon arrival, significantly shortening diagnostic turnaround time.
High-sensitivity nucleic acid detection to support precision public health control
Built on real-time fluorescent PCR technology, the assay delivers far higher sensitivity and specificity than rapid antigen tests, and can detect low viral load samples in early-stage infection. It reduces missed diagnosis rates, supports early detection, isolation and control of arboviral infections, and facilitates efficient outbreak response and epidemiological surveillance.
Core Product Advantages
Dual-purpose 8-plex panel design for clinical and public health scenarios
The panel covers 8 WHO-prioritized pathogenic arboviruses, including all 4 dengue serotypes, and is fully suited for acute febrile illness differential diagnosis, tropical disease care, travel medicine, entry-exit port quarantine and outbreak emergency screening, meeting the needs of both tertiary hospitals and public health agencies.
Fully automated closed sample-to-result workflow
Leveraging proprietary centrifugal microfluidic technology, the kit integrates two gold-standard workflows — silica membrane-based nucleic acid extraction and multiplex real-time qPCR — within a single enclosed disposable cartridge. Only 1 minute of manual pipetting is required, with no professional molecular operation expertise needed, delivering true "load-and-go" detection.

Flexible throughput adapted to diverse testing scenarios
Compatible with the Multi-Disc (Model: CQ-0404) Fully Automated Nucleic Acid Analyzer, the platform supports parallel testing of 4 samples per run with full results available in around 80 minutes. It supports flexible 1–4 sample loading without batch accumulation, adapting seamlessly to sporadic outpatient testing, on-demand port quarantine and mass outbreak screening.
Lyophilized reagents for room-temperature storage and transport
With our self-developed PCR reagent lyophilization process, pre-embedded lyophilized reagent beads in the microfluidic chip enable room-temperature storage and transportation, eliminating cold chain reliance and greatly reducing storage and logistics costs for tropical regions, remote endemic areas and field testing sites.
Zero cross-contamination closed cartridge system
Each sample is processed in an individual sealed disposable cartridge, with amplification products never exposed to the external environment. This design fundamentally eliminates aerosol cross-contamination, reduces on-site quality control burdens, and ensures stable, reliable results even in non-laboratory settings.
CE-compliant with validated clinical sample compatibility
The assay is fully validated for human serum and EDTA-anticoagulated plasma samples. All 8 targets are CE-marked, meeting regulatory requirements for clinical diagnosis, public health surveillance and border quarantine across global markets.